Red Yeast RiceMonascus purpureus fermentate · 4 claims

The EFSA NDA Panel concluded that a cause and effect relationship had been established between consumption of 10 mg/day of monacolin K from red yeast rice and the claimed cholesterol-lowering effect. That is a stronger regulatory statement than almost any supplement receives.

The catch is the dose. 10 mg/day is above the level the European Commission now permits in supplements, and it is the level at which EFSA identified significant safety concern.

EFSA also concluded that the composition and content of the minor monacolins in these products is variable, and that available data do not allow their contribution to the cholesterol-lowering effect to be evaluated.

• RegEFSA ANS Panel. Scientific opinion on the safety of monacolins in red yeast rice EFSA Journal 2018 · doi 10.2903/j.efsa.2018.5368
• RegEFSA NDA Panel. Additional scientific data related to the safety of monacolins from red yeast rice EFSA Journal 2025 · doi 10.2903/j.efsa.2025.9276

Monacolin K in lactone form is identical to lovastatin — the active ingredient of prescription medicines authorised across the EU for high cholesterol. EFSA states this plainly.

Taking red yeast rice can therefore expose you to monacolin K within the therapeutic dose range of lovastatin, 10 to 80 mg/day, without a prescription, without dose control, without liver monitoring and without anyone checking what else you take.

The French agency ANSES put it directly: because red yeast rice contains monacolin K, which shares the adverse effects of statins, plus other monacolins whose safety has not been established, consuming it exposes some consumers to a health risk.

• RegEFSA ANS Panel opinion, including the ANSES position on red yeast rice EFSA Journal 2018;16(8):5368

EFSA judged the human adverse effect reports sufficient to conclude significant safety concern at 10 mg/day, and noted individual cases of severe adverse reactions at intakes as low as 3 mg/day. Reported effects include rhabdomyolysis and liver injury.

A fair counterweight: an analysis of the FDA and CFSAN adverse event systems from 2013 to 2023 found that of 363,879 musculoskeletal cases reported, those linked to red yeast rice accounted for 0.008%. The pharmacology is concerning; the observed reporting rate is low.

Both things are true, and the resolution is the same either way: this is a statin, so it deserves statin-level caution about interactions and monitoring.

• RegEFSA ANS Panel: adverse effects on musculoskeletal system and liver Significant concern at 10 mg/day; severe cases at 3 mg/day
• RevThe impact of red yeast rice extract use on muscle symptoms and liver dysfunction: update from adverse event reporting systems and meta-analyses FAERS and CAERS analysis, Sept 2013 to Sept 2023

Thirty-five red yeast rice supplements bought from an EU e-commerce platform and registered online pharmacies were tested by validated LC-MS/MS. At least four (roughly 11%) gave cause for concern — three exceeded the European limits on total monacolin content, and there was severe bacterial contamination.

Products were also screened for deliberate adulteration with pharmaceutical lovastatin, by examining the ratio of monacolin K forms.

So most products were compliant. But when the compound in question is a statin at an uncontrolled dose, a one-in-nine failure rate is a different kind of problem from a one-in-nine failure rate on vitamin C.

• LabQuality control and safety assessment of online-purchased food supplements containing red yeast rice 35 supplements, LC-MS/MS validated to ISO 17025